Puma Biotechnology, Inc. PBYI was a big mover last session, as the company saw its shares rise over 10% on the day. The move came on the company’s announcement of interim results from the ongoing phase II study on breast cancer drug PB272 on Friday. This led to solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 9.3% in the last one month.
The company has seen no estimate revisions in the past 30 days and the Zacks Consensus Estimate has also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Puma Biotechnology currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
A better-ranked biotechnology stock is Anika Therapeutics Inc. ANIK, sporting a Zacks Rank #1 (Strong Buy).
Is PBYI going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment